Patents by Inventor Kalyana Chakravarthi Dulla

Kalyana Chakravarthi Dulla has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antisense oligonucleotides for the treatment of Stargardt disease
    Patent number: 12180471
    Abstract: The invention relates to the fields of medicine and biotechnology. In particular, it relates to novel antisense oligonucleotides (AONs) that may be used in the treatment, prevention and/or delay of Stargardt disease and/or ABCA4-associated eye disease. More in particular, the invention relates to AONs that are used in inhibiting or blocking exon 39 skipping in the human ABCA4 pre-mRNA.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: December 31, 2024
    Assignee: ProQR Therapeutics II B.V.
    Inventors: Aliye Seda Yilmaz-Elis, Peter Adamson, Kalyana Chakravarthi Dulla, Iris Antoinette Ernestine Schulkens
  • ASSESSMENT OF CELLULAR SIGNALING PATHWAY ACTIVITY USING PROBABILISTIC MODELING OF TARGET GENE EXPRESSION
    Publication number: 20230105263
    Abstract: The present application mainly relates to specific methods for inferring activity of one or more cellular signaling pathway(s) in tissue of a medical subject based at least on the expression level(s) of one or more target gene(s) of the cellular signaling pathway(s) measured in an extracted sample of the tissue of the medical subject, an apparatus comprising a digital compressor configured to perform such methods and a non-transitory storage medium storing instructions that are executable by a digital processing device to perform such methods.
    Type: Application
    Filed: August 24, 2022
    Publication date: April 6, 2023
    Applicant: InnoSIGN B.V.
    Inventors: WILHELMUS FRANCISCUS JOHANNES VERHAEGH, ANJA VAN DE STOLPE, HENDRIK JAN VAN OOIJEN, KALYANA CHAKRAVARTHI DULLA, MARCIA ALVES DE INDA, RALF HOFFMAN
  • Assessment of cellular signaling pathway activity using probabilistic modeling of target gene expression
    Patent number: 11443831
    Abstract: The present application mainly relates to specific methods for inferring activity of one or more cellular signaling pathway(s) in tissue of a medical subject based at least on the expression level(s) of one or more target gene(s) of the cellular signaling pathway(s) measured in an extracted sample of the tissue of the medical subject, an apparatus comprising a digital compressor configured to perform such methods and a non-transitory storage medium storing instructions that are executable by a digital processing device to perform such methods.
    Type: Grant
    Filed: July 19, 2012
    Date of Patent: September 13, 2022
    Assignee: InnoSIGN B.V.
    Inventors: Wilhelmus Franciscus Johannes Verhaegh, Anja Van De Stolpe, Hendrik Jan Van Ooijen, Kalyana Chakravarthi Dulla, Marcia Alves De Inda, Ralf Hoffmann
  • ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF USHER SYNDROME
    Publication number: 20220213478
    Abstract: The invention relates to the fields of medicine. In particular, it relates to novel antisense oligonucleotides (AONs) that are capable of skipping exon 62 from human USH2A premRNA and that may be used in the treatment, prevention and/or delay of Usher syndrome type II and/or USH2A-associated non syndromic retina degeneration.
    Type: Application
    Filed: April 17, 2020
    Publication date: July 7, 2022
    Inventors: Jim Swildens, Maarten Holkers, Sunseeahray Eugenie Elizabeth Naomi Mahakena, Kalyana Chakravarthi Dulla, Hee Lam Chan
  • RNA-EDITING OLIGONUCLEOTIDES FOR THE TREATMENT OF USHER SYNDROME
    Publication number: 20220112495
    Abstract: The invention relates to RNA editing oligonucleotides that are capable of bringing about specific editing of a target nucleotide (adenosine) in a target RNA molecule in a eukaryotic cell, wherein said oligonucleotide is for use in the treatment of Usher syndrome, and more preferably for the deamination of target adenosines that are part of a premature stop codon present in the USH2A pre-mRNA or USH2A mRNA.
    Type: Application
    Filed: January 27, 2020
    Publication date: April 14, 2022
    Inventors: Lenka Van Sint Fiet, Kalyana Chakravarthi Dulla, Jim Swildens
  • ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF LEBER`S CONGENITAL AMAUROSIS
    Publication number: 20220098584
    Abstract: The invention relates to antisense oligonucleotides (AON) capable of inducing the skip of exon 36 from human CEP290 pre-mRNA. The c.4723A>T mutation in the human CEP290 gene is the cause of Leber's Congenital Amaurosis type 10 (LCA10) in patients carrying this mutation. The AONs of the present invention can be used in the treatment of LCA10 caused by mutations in exon 36, such as the c.4723A>T mutation. The invention relates to AONs, pharmaceutical formulations comprising such AONs, and viral vectors expressing such AONs, that may be used in the treatment of LCA10.
    Type: Application
    Filed: January 27, 2020
    Publication date: March 31, 2022
    Inventors: Jim Swildens, Jeroen van de Giessen, Kalyana Chakravarthi Dulla
  • ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF STARGARDT DISEASE
    Publication number: 20210115439
    Abstract: The invention relates to the fields of medicine and biotechnology. In particular, it relates to novel antisense oligonucleotides (AONs) that may be used in the treatment, prevention and/or delay of Stargardt disease and/or ABCA4-associated eye disease. More in particular, the invention relates to AONs that are used in inhibiting or blocking exon 39 skipping in the human ABCA4 pre-mRNA.
    Type: Application
    Filed: April 13, 2018
    Publication date: April 22, 2021
    Inventors: Aliye Seda Yilmaz-Elis, Peter Adamson, Kalyana Chakravarthi Dulla, Iris Antoinette Ernestine Schulkens